Choriocarcinoma: Difference between revisions
Line 35: | Line 35: | ||
== Etiology/Epidemiology == | == Etiology/Epidemiology == | ||
It is preceded by: | It is preceded by: | ||
* [[ | * [[Hydatidiform mole]] (50% of cases) | ||
* Spontaneous abortion (20%of cases) | * [[Spontaneous abortion]] (20% of cases) | ||
* [[ | * [[Ectopic pregnancy]] (2% of cases) | ||
* | * Normal term [[pregnancy]] (20-30% of cases) | ||
==Symptoms/Signs/Labs== | ==Symptoms/Signs/Labs== |
Revision as of 01:14, 14 January 2009
Choriocarcinoma | |
ICD-10 | C58 |
---|---|
ICD-9 | 181 |
ICD-O: | 9100-9101 |
DiseasesDB | 2602 |
MeSH | D002822 |
WikiDoc Resources for Choriocarcinoma |
Articles |
---|
Most recent articles on Choriocarcinoma Most cited articles on Choriocarcinoma |
Media |
Powerpoint slides on Choriocarcinoma |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Choriocarcinoma at Clinical Trials.gov Trial results on Choriocarcinoma Clinical Trials on Choriocarcinoma at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Choriocarcinoma NICE Guidance on Choriocarcinoma
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Choriocarcinoma Discussion groups on Choriocarcinoma Patient Handouts on Choriocarcinoma Directions to Hospitals Treating Choriocarcinoma Risk calculators and risk factors for Choriocarcinoma
|
Healthcare Provider Resources |
Causes & Risk Factors for Choriocarcinoma |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Choriocarcinoma is a malignant and aggressive cancer of the placenta. It is characterized by early hematogenous spread to the lungs. It belongs to the far end of the spectrum of gestational trophoblastic diseases (GTD).
Classification of GTDs
Broadly, gestational trophoblastic diseases can be classified in the following:
- a. Complete Mole
- b. Partial Mole
2. Invasive Mole
3. Choriocarcinoma
4. Placental site trophoblastic tumor
Etiology/Epidemiology
It is preceded by:
- Hydatidiform mole (50% of cases)
- Spontaneous abortion (20% of cases)
- Ectopic pregnancy (2% of cases)
- Normal term pregnancy (20-30% of cases)
Symptoms/Signs/Labs
- increased quantitative β-hCG levels
- vaginal bleeding
- shortness of breath
- hemoptysis (coughing up blood)
- chest pain
- chest X-ray shows multiple infiltrates of various shapes in both lungs
- presents in males as a testicular neoplasm
Pathology
On light microscopy, there is malignant trophoblastic proliferation without hydropic villi.
Treatment
Choriocarcinoma is one of the tumors that is most sensitive to chemotherapy. The cure rate, even for metastatic choriocarcinoma, is around 90-95%. Virtually everyone without metastases can be cured however metastatic disease to the kidneys and/or brain is usually fatal. Chemotherapy regimen include EMACO (etoposide, methotrexate, actinomycin D, cyclosphosphamide and oncovin).
Hysterectomy (surgical removal of the uterus) can also be offered to patients > 40 years of age or those desiring sterilization. It may be required for those with severe infection and uncontrolled bleeding.
External Links
- MyMolarPregnancy.com Support group, information, links and personal stories for women with molar pregnancies at mymolarpregnancy.com
- Template:Chorus